HIV疫苗的全球市場與未來展望

過去數十年來，HIV疫苗的藥物研發和設計，研究開發積極進行，每年皆有新品種的疫苗開發。因此，達成HIV的預防、治療相關顯著的成果。近幾年尤其積極進行使用了重組DNA技術和基因工程學的疫苗開發。今後這個氣勢也將持續，各國政府和製藥產業繼續投入大金額的開發資金。

本報告提供全球各國HIV (人類免疫缺陷病毒) 疫苗市場趨勢，及開發平台產品的開發情形相關分析、HIV疫苗的特性和作用機制、整體市場結構、趨勢、開發中產品的目前開發情形主要課題、產品單位 (共100種產品) 及各臨床實驗階段的詳細的開發情形、已上市產品 (共42種產品) 銷售情形、今後的市場方向性的資訊，為您概述為以下內容。

第1章 HIV疫苗概要

第2章 HIV疫苗的開發相關課題

• 抗原性的不足
• HIV的多相性
• 突然變異率的高度
• 免疫系的不全
• 跟DNA的一體化

第3章 HIV疫苗的順利商業化的指標

• 長期的功效
• 預防感染
• 復發預防
• 成本效率性
• 製造工程的可擴展性

第4章 HIV疫苗的作用機制

第5章 全球HIV疫苗的市場機會分析

• 市場概況
• HIV疫苗的臨床實驗平台概要

第6章 全球的HIV發病率

第7章 全球HIV疫苗市場動態

• HIV疫苗的資金籌措方案
• 有正面作用的市場參數
• HIV疫苗的商業化相關課題

第8章 全球HIV疫苗的未來展望

第9章 全球HIV疫苗的臨床實驗平台:各企業、各Phase

• 研究階段
• 前臨床
• 臨床
• 第一階段
• 第一/二階段
• 第二階段
• 第三階段
• 認證前

第10章 臨床實驗中止、延期之臨床實驗平台上的HIV疫苗

• 沒有開發報告
• 臨床實驗中止
• 臨床實驗延期

第11章 競爭環境

• AlphaVax
• Antigen Express
• Argo Therapeutics
• Bionor Pharmaceuticals
• Celldex Therapeutics
• FIT Biotech
• Crucell Pharmaceutical
• GeneCure
• Genetic Immunity
• GenVec
• GeoVax Labs
• Glaxo Smithkline
• Immune Response BioPharma
• Inovio Pharmaceuticals
• Novartis
• Oncolys Biopharma
• PaxVax
• Profectus Biosciences
• Sanofi
• TVAX Biomedical

圖表一覽

Vaccine discovery, designing, research and development science is backed by several decades of knowledge. Every year, new vaccine for treating infectious diseases is entering in the market and their quality along with pharmacological efficacy is increasing. Innovative modalities have been found and market is overcrowded with the number of vaccines for different infectious diseases. In this scenario, absence of HIV vaccines becomes a pertinent question in front of investigators funded by both pharmaceutical companies and medical regulatory authorities. Gravity of the situation could also be understood by the fact that HIV clinical trials have failed to produce pharmacological benefits despite availability of suitable infrastructure. Simultaneously, HIV incidences are escalating tremendously across the globe due to which necessity for this vaccine is becoming more essential. All these facts support the imminent market introduction of HIV vaccines in global market to prevent progression and proliferation of AIDS epidemic.

Clinical trials are being done for across the globe for development of HIV vaccines and these efforts have yielded significant results. Investigators have identified artificial molecules that could mimic the HIV infection as result of which immune system would be activated. Their efficacy has been proved and clinical trials using them have yet to instigate. Several different modalities are also under investigation which may lead to development of relatively high cure rates. Certain receptors are also under investigation which has been found to be involved during initial phase of HIV infection. Immunoglobins may also serve as an ideal candidate due to their involvement in immune system activation. Beside this, several innovative modalities has been proposed for the treatment of HIV and emphasis is being given on the development of prophylactic vaccines. Several lead molecules have been discovered and their pharmacological efficacy is under investigation. In this way, investigators are expected to find some worthy candidate to the development of HIV vaccine.

Recombinant DNA technologies and genetic engineering has been widely used for the development of vaccines for several infectious diseases. These technologies are also being used for the development of HIV vaccines that would be commercialized in global market in coming years. Genetic manipulation of HIV is under consideration to develop a strain which have all molecular signatures but no pathogenicity. This decoy strain will activate the immune system to develop active immunity. Novel modalities include, use of recombinant molecules having higher immune eliciting capabilities. Computerized simulations are also being used for analysis of obscure vaccine candidates having pharmaceutical potential. This technology is expected to decrease the valuable time and precious resources utilized in the screening of proposed candidate. Furthermore, investigators are developing methodologies to find the effect of HIV gene expression on nonpathogenic bacterial/viral vectors.

Pharmaceutical companies have recognized the dearth of effective HIV medications due to which they are investing significant amount on research and development of HIV vaccines. Various candidates are at different stages of clinical trials and they would be introduced in market in coming years. Technology is developing at rapid rates due to which screening of selected candidate is expected to take place at lesser time. In this way, market winding times are expected to decrease due to lesser time in developmental phases. Manufacturing capabilities are highly developed but some tweaking has to be done according to HIV pathogen. Significant development in recombinant DNA technology and genetic engineering is also expected to accelerate the rate of HIV vaccine development. Investigators are also expected to find new modalities that will help in checking the AIDS. In this way, future of HIV vaccines market looks optimistic and it may be commercialized in next 5-10 years.

"Global HIV Vaccine Market Future Outlook" Report Highlights:

• Introduction to HIV Vaccines
• Issues Related to the Development of HIV Vaccines
• Parameters for Successful Commercialization of HIV Vaccines
• Global HIV Vaccines Market Opportunity Analysis
• Global HIV Vaccine Clinical Pipeline by Company & Phase
• Global HIV Vaccine Clinical Pipeline: 100 Vaccines
• Majority Vaccine in Preclinical Phase: 42 Vaccines

Table of Contents

1. Introduction to HIV Vaccines

2. Issues Related to the Development of HIV Vaccines

• 2.1. Lack of Antigenicity
• 2.2. HIV Polymorphism
• 2.3. High Mutation Rates
• 2.4. Compromised Immune System
• 2.5. Integration with DNA

3. Parameters for Successful Commercialization of HIV Vaccines

• 3.1. Long Term Efficacy
• 3.2. Reduced Transmission
• 3.3. Relapse Prevention
• 3.4. Cost Effectiveness
• 3.5. Manufacturing Scalability

4. Mechanism of HIV Vaccines

5. Global HIV Vaccines Market Opportunity Analysis

• 5.1. Market Overview
• 5.2. HIV Vaccine Clinical Pipeline Overview

6. Global HIV Incidence Rates

7. Global HIV Vaccine Market Dynamics

• 7.1. Funding Scenario for HIV Vaccine
• 7.2. Favorable Market Parameters
• 7.3. HIV Vaccines Commercialization Challenges

8. Global HIV Vaccines Market Future Prospects

9. Global HIV Vaccine Clinical Pipeline by Company & Phase

• 9.1. Research
• 9.2. Preclinical
• 9.3. Clinical
• 9.4. Phase-I
• 9.5. Phase-I/II
• 9.6. Phase-II
• 9.7. Phase-III
• 9.8. Preregistration

10. Discontinued & Suspended HIV Vaccines in Clinical Pipeline by Company & Phase

• 10.1. Discontinued
• 10.2. Suspended
• 10.3. No Development Reported

11. Competitive Landscape

• 11.1. AlphaVax
• 11.2. Antigen Express
• 11.3. Argo Therapeutics
• 11.4. Bionor Pharmaceuticals
• 11.5. Celldex Therapeutics
• 11.6. FIT Biotech
• 11.7. Crucell Pharmaceutical
• 11.8. GeneCure
• 11.9. Genetic Immunity
• 11.10. GenVec
• 11.11. GeoVax Labs
• 11.12. Glaxo Smithkline
• 11.13. Immune Response BioPharma
• 11.14. Inovio Pharmaceuticals
• 11.15. Novartis
• 11.16. Oncolys Biopharma
• 11.17. PaxVax
• 11.18. Profectus Biosciences
• 11.19. Sanofi
• 11.20. TVAX Biomedical

List of Figures

• Figure 1-1: Effects of HIV Disease
• Figure 1-2: Methods of HIV Transmission
• Figure 1-3: Modalities to Treat HIV Infection
• Figure 2-1: Issues Related to the Development of HIV Vaccines
• Figure 3-1: Requirements for Successful Commercialization of HIV Vaccines
• Figure 4-1: Types of HIV Vaccines
• Figure 4-2: Techniques to Develop HIV Vaccines
• Figure 4-3: Mechanism of SAV001 Vaccine
• Figure 4-4: Mechanism of AIDSVAX HIV Vaccine
• Figure 4-5: Mechanism of V520 HIV Vaccine
• Figure 5-1: HIV Vaccine Clinical Pipeline by Phase (%), 2015
• Figure 5-2: HIV Vaccine Clinical Pipeline by Phase (Number), 2015
• Figure 5-3: No Development Reported HIV Vaccine Clinical Pipeline by Phase (%), 2015
• Figure 5-4: No Development Reported HIV Vaccine Clinical Pipeline by Phase (Number), 2015
• Figure 5-5: Discontinued HIV Vaccine Clinical Pipeline by Phase (%), 2015
• Figure 5-6: Discontinued HIV Vaccine Clinical Pipeline by Phase (Number), 2015
• Figure 6-1: People Living With HIV Infection (Million), 2009-2014
• Figure 6-2: New Incidence of HIV Infection (Million), 2009-2012
• Figure 7-1: Global HIV Vaccines R&D Funding (US$ Million), 2005-2012
• Figure 7-2: Global HIV Vaccines R&D Funding Breakup (%), 2012
• Figure 7-3: Philanthropic Sector Spending on HIV Vaccines by Clinical Research Phase (%), 2012
• Figure 7-4: HIV Vaccine Market Favorable Parameters
• Figure 7-5: HIV Vaccines Commercialization Challenges
• Figure 8-1: Estimated HIV Market Size with Routine Vaccination Only
• Figure 11-1: AlphaVax Clinical Pipeline
• Figure 11-2: Bionor Pharma Clinical Pipeline
• Figure 11-3: TVAX Biomedical Clinical Pipeline

List of Tables

• Table 4-1: HIV Vaccine Antigens under Investigation
• Table 6-1: Comparative Analysis of HIV Associated Features across the Globe
• Table 7-1: HIV Vaccines Funding by Sector (US$ Million), 2006-2012
• Table 8-1: Global Impact of a Vaccine on AIDS Incidence and Mortality